Lung cancer is one of the leading causes of cancer-related deaths in Japan, making its early detection and treatment a critical issue in the medical field. Research in this area is progressing not only in Japan but also globally. Among the pioneers leading these advancements is Dr. Harufumi Kato, a foremost expert in lung cancer diagnosis and treatment, who has saved many lives with his innovative approaches. With decades of research and clinical experience, Dr. Kato remains at the forefront of lung cancer care. In this article, we explore his achievements, the importance of cancer screening, and the latest treatment methods.
Profile: Dr. Harufumi Kato
Background
Graduated from Tokyo Medical University; completed graduate studies at the same university; studied at the Karolinska Institute in Sweden; Former Professor and Chair of the First Department of Surgery at Tokyo Medical University; Vice President of Tokyo Medical University; Director of the Clinical Proteomics Center at Tokyo Medical University.
Held positions including President of the International Academy of Cytology, President and Director of the International Association for the Study of Lung Cancer (IASLC), President of the International Bronchoesophagological Society, President of the Japan Society of Medical Science, President of the Japanese Society of Clinical Cytology, President and Director of the Japan Lung Cancer Society, Councilor and Board Member of the Japan Surgical Society, the Japanese Association for Thoracic Surgery, the Japan Society for Respiratory Endoscopy, and the Japanese Respiratory Society; Board Member of the Japanese Society of Medical Oncology, the Japanese Cancer Association, President of the Japan Society for Laser Medicine, President of the International Society for Laser Surgery and Medicine, President of the International Photodynamic Association, and President of the Japanese Society for Clinical Proteomics and Photodynamic Medicine, among others.
Governmental Roles
Served as an expert for agencies including the Science and Technology Agency, the Ministry of International Trade and Industry, the Ministry of Health and Welfare, the Science Council of Japan, the Ministry of Education, the Ministry of Education, Culture, Sports, Science and Technology (MEXT), the Japan Medical Association, and the Ministry of Health, Labour and Welfare.
Awards
1986: Japan Society of Clinical Cytology Award 1997: Ikeda Award, Japan Bronchoesophagological Society 1998: Goldblatt Award, International Academy of Cytology (USA) 1999: Distinguished Fellow Award, International Academy of Chest Physicians (USA) 2005: “von Tappeiner” Medal, International Photodynamic Association (Germany) 2005: IASLC Merit Award (USA) 2007: Japan Medical Association Merit Award 2017: Song Eum Prize (Korea) 2019: Gold Medal Award, International Photodynamic Association (USA)
Why Is Early Detection of Lung Cancer So Important?
Lung cancer progresses rapidly and is often already advanced by the time symptoms appear. In the early stages, it typically presents no noticeable symptoms, and many cases are diagnosed too late. Therefore, early detection is key to improving survival rates. With recent advancements in CT scanning technology, even small cancers that were difficult to detect with traditional chest X-rays can now be diagnosed early, allowing more patients to receive appropriate treatment in time.
How Does CT Scanning Differ from Traditional Tests?
Traditional chest X-rays often fail to detect tumors until they reach a certain size, making early-stage diagnosis difficult. Many small cancers were missed, and by the time they were discovered, they were already advanced. In contrast, CT scans can detect tumors as small as a few millimeters, making them significantly superior for early detection.
Moreover, modern CT technology offers high-resolution images while minimizing radiation exposure, improving safety. For high-risk individuals, such as smokers and those with a family history of lung cancer, regular CT scans greatly enhance the chances of early detection. AI-assisted diagnostic systems are also being introduced, enabling faster and more accurate diagnoses.
What Is Photodynamic Therapy (PDT)?
Photodynamic therapy (PDT) is a treatment method that uses a light-sensitive drug that selectively accumulates in cancer cells. When the area is exposed to laser light, the cancer cells are destroyed while minimizing damage to healthy tissue. Unlike traditional surgery, PDT effectively targets only the cancer cells.
This treatment is especially beneficial for patients who are not suitable candidates for surgery. For elderly patients or those with compromised heart or lung function, PDT offers a valuable treatment alternative.
Who Is a Candidate for PDT?
PDT is mainly used for early-stage lung cancer patients, but it is also effective for the following types of patients:
- Elderly patients for whom surgery is difficult
- Patients who have not responded well to existing treatments
- Patients with other cancers such as esophageal or gastric cancer
This therapy continues to evolve and is expected to be applied to an increasing number of cancer types. We aim to further develop this treatment and make it available to more patients in the future.
Efforts to Improve Cancer Screening Rates
Increasing cancer screening rates is a major goal for the medical community. Since early detection of lung cancer directly correlates with higher survival rates, we strongly recommend regular CT screening. Through the Japan Society of Medical Science, I promote awareness and work with local governments and corporations to expand opportunities for workplace and community screenings.
People who smoke or have family members affected by lung cancer are at higher risk and should prioritize early testing. Recently, we’ve launched awareness campaigns through online platforms and free screening events to emphasize the importance of regular checkups.
Global Recognition and Future Outlook
My research has received international recognition, including the 1998 Goldblatt Award from the International Academy of Cytology and the 2005 “von Tappeiner” Medal from the International Photodynamic Association. These awards are not solely my achievement but the result of collaborative efforts with many healthcare professionals. I will continue contributing to advancements in lung cancer diagnostics.
I also plan to pursue the development of AI-assisted diagnostic tools and broaden the applications of PDT. Spreading awareness of cancer screening and reducing the number of people suffering from lung cancer remain my top priorities.
It is essential to understand the importance of early detection and treatment of lung cancer and to undergo regular cancer screenings. I hope this article helps convey that message to a wider audience.
